Development of an adjuvant therapy for severe malaria with the hemoglobin vesicle, an artificial oxygen carrier.

点击翻译按钮获取中文摘要

We investigated the potential of HbV as an adjuvant therapy for severe malaria using rodent malaria models. Balb/c mice were inoculated with Plasmodium berghei. The HbV or saline infection was started in tail vein from 6-day after inoculation. No significant difference in parasitemia and body weight of the mice was observed between the HbV and saline treated groups after daily treatment until they died. However, we observed that, immediately after its administration, the HbV treated mice became more active comparing the saline treated mice. To evaluate the effects of the HbV treatment, the rotarod performance test was carried out. The riding time on the rotarod compared between the 2 groups revealed significant extension of the time in mice treated with the HbV. The HbV transfusion may have improved the anemia and mitigated the complication of severe malaria in mice. The HbV has high potential as adjuvant therapy for human as well to save the lives of patients in the endemic areas.